{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:25:29Z","timestamp":1777947929608,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jad.2025.03.028","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:05:14Z","timestamp":1741694714000},"page":"266-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Real-world Effectiveness and Tolerability of Lurasidone in Outpatients with Bipolar DisorderII- A 24\u00a0week retrospective study (RETLO-BDIIstudy)"],"prefix":"10.1016","volume":"379","author":[{"given":"Sho","family":"Horikoshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichiro","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizue","family":"Ichinose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Kanno-Nozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jad.2025.03.028_bb0005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2165\/00023210-200721090-00003","article-title":"Bipolar II disorder: epidemiology, diagnosis and management","volume":"21","author":"Benazzi","year":"2007","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.jad.2025.03.028_bb0020","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.euroneuro.2017.06.013","article-title":"Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder","volume":"27","author":"Calabrese","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.jad.2025.03.028_bb0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4088\/JCP.10m06314","article-title":"Early response and remission as predictors of a good outcome of a major depressive episode at 12-month follow-up: a prospective, longitudinal, observational study","volume":"73","author":"Ciudad","year":"2012","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.jad.2025.03.028_bb0040","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/jamapsychiatry.2013.1394","article-title":"Comorbidities and mortality in bipolar disorder: a Swedish national cohort study","volume":"70","author":"Crump","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2025.03.028_bb0050","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40345-023-00302-x","article-title":"Rates and associations of relapse over 5 years of 2649 people with bipolar disorder: a retrospective UK cohort study","volume":"11","author":"Hett","year":"2023","journal-title":"Int. J. Bipolar Disord."},{"issue":"1","key":"10.1016\/j.jad.2025.03.028_bb0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1\u20132","key":"10.1016\/j.jad.2025.03.028_bb0070","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jad.2010.10.026","article-title":"Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression","volume":"130","author":"Kemp","year":"2011","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.jad.2025.03.028_bb0080","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/da.22479","article-title":"Lurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension study","volume":"33","author":"Ketter","year":"2016","journal-title":"Depress. Anxiety"},{"issue":"2","key":"10.1016\/j.jad.2025.03.028_bb0090","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/npp.2009.164","article-title":"Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia","volume":"35","author":"Kinon","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.jad.2025.03.028_bb0100","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1399-5618.2004.00158.x","article-title":"Demographic and diagnostic characteristics of the first 1000 patients enrolled in the systematic treatment enhancement program for bipolar disorder (STEP-BD)","volume":"6","author":"Kogan","year":"2004","journal-title":"Bipolar Disord."},{"issue":"2","key":"10.1016\/j.jad.2025.03.028_bb0110","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","article-title":"Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2025.03.028_bb0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/acps.12087","article-title":"Employment outcomes in people with bipolar disorder: a systematic review","volume":"128","author":"Marwaha","year":"2013","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.jad.2025.03.028_bb0130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/YCO.0b013e32834de3de","article-title":"The \u2018true\u2019 prevalence of bipolar II disorder","volume":"25","author":"Merikangas","year":"2012","journal-title":"Curr. Opin. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2025.03.028_bb0140","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archgenpsychiatry.2011.12","article-title":"Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative","volume":"68","author":"Merikangas","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2025.03.028_bb0150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11920-020-1130-0","article-title":"Bipolar disorder and suicide: a review","volume":"22","author":"Miller","year":"2020","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.jad.2025.03.028_bb0160","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.2147\/DDDT.S366769","article-title":"Lurasidone for the treatment of schizophrenia: design, development, and place in therapy","volume":"17","author":"Miura","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"issue":"8","key":"10.1016\/j.jad.2025.03.028_bb0170","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1080\/15622975.2017.1285050","article-title":"Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: a systematic review and network meta-analysis","volume":"19","author":"Ostacher","year":"2018","journal-title":"World J. Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.jad.2025.03.028_bb0180","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/2045125318769235","article-title":"Epidemiology and risk factors for bipolar disorder","volume":"8","author":"Rowland","year":"2018","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.jad.2025.03.028_bb0190","first-page":"439","article-title":"Long-term prognosis of depression in primary care","volume":"78","author":"Simon","year":"2000","journal-title":"Bull. World Health Organ."},{"issue":"5","key":"10.1016\/j.jad.2025.03.028_bb0200","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/JCP.0000000000001590","article-title":"Effectiveness and tolerability of Lurasidone for bipolar types I and II and other specified bipolar depression: a 12-week observational study","volume":"42","author":"Takaesu","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.jad.2025.03.028_bb0210","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian network for mood and anxiety treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725003660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725003660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T04:27:29Z","timestamp":1777782449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725003660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":21,"alternative-id":["S0165032725003660"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.03.028","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Effectiveness and Tolerability of Lurasidone in Outpatients with Bipolar DisorderII- A 24\u00a0week retrospective study (RETLO-BDIIstudy)","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}